Crizotinib Failure in a TPM4-ALK-Rearranged Inflammatory Myofibroblastic Tumor With an Emerging ALK Kinase Domain Mutation

Affiliation

• ¹ Kalliopi Tsakiri, Vassiliki Kotoula, Mattheos Bobos, and George Fountzilas, Hellenic Foundation for Cancer Research; Vassiliki Kotoula, Prodromos Hytiroglou, and George Fountzilas, Aristotle University of Thessaloniki, Thessaloniki; Kalliopi Tsakiri and George Fountzilas, Thermi Oncology Unit, Thermi; Florentia Fostira, National Center for Scientific Research Demokritos, Athens, Greece; and Sotirios Lakis and Judith Müller, New Oncology, Cologne, Germany.